Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Friday, Zacks reports.
Other research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Lake Street Capital initiated coverage on Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Finally, HC Wainwright reiterated a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aligos Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.50.
Aligos Therapeutics Stock Performance
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.95. The company had revenue of $27.78 million during the quarter, compared to analyst estimates of $24.68 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. As a group, equities analysts forecast that Aligos Therapeutics will post -6.81 EPS for the current fiscal year.
Institutional Trading of Aligos Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of ALGS. Bank of America Corp DE lifted its stake in shares of Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after acquiring an additional 216,646 shares in the last quarter. SummitTX Capital L.P. grew its stake in Aligos Therapeutics by 6.7% during the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Renaissance Technologies LLC grew its stake in Aligos Therapeutics by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after purchasing an additional 15,006 shares in the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares during the last quarter. 60.43% of the stock is owned by hedge funds and other institutional investors.
About Aligos Therapeutics
Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs.
Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression.
See Also
- Five stocks we like better than Aligos Therapeutics
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
